Cistanches Herba, from an endangered species to a big brand of Chinese medicine. Issue 3 (31st January 2021)

• Record Type: Journal Article
• Authors: Song, Yuelin; Zeng, Kewu; Jiang, Yong; Tu, Pengfei
• Is Part Of: Medicinal research reviews. Volume 41:Issue 3(2021)
• Page Start: 1539
• Page End: 1577
• Publication Date: 2021-01-31
• Subjects: big brand Chinese medicine -- Cistanches Herba -- cultivation -- echinacoside -- health product; Pharmacology -- Periodicals; Drugs -- Research -- Periodicals; 615
• DOI: 10.1002/med.21768
• Languages: English
• ISSNs: 0198-6325

Abstract

Abstract: Cistanches Herba (CH, Chinese name: Roucongrong ), is a very precious, tonic Chinese medicine. Cistanche deserticola and Cistanche tubulosa are the two commonly used species and authenticated in Chinese Pharmacopoeia. Due to the parasitic nature of Cistanche plants, the wild source was once endangered and listed in the Appendix II of Convention on International Trade in Endangered Species of Wild Fauna and Flora. However, after continuously struggling in the past decades, CH has grown up to a big brand of Chinese medicine featured with the cultivation area as 1.26 million mu, the annual output as 6000 tons, and the related industrial output value as more than 20 billion China Yuan, attributing to large‐scale cultivation and in‐depth phytochemical and pharmacological investigations. Noteworthily, great achievements have reached concerning the research and development of relevant products, such as modern drugs, traditional Chinese medicine prescriptions, and dietary supplements. The current review summarizes the research progresses concerning the distribution and cultivation, phytochemistry, pharmacology, metabolism and product development of CH in the past decades, and the emerging challenges and developing prospects are discussed as well.